Subtleties in GPCR drug discovery: A medicinal chemistry perspective

Drug Discovery Today

Volumn 17, Issue 19-20, 2012, Pages 1133-1138

  Fujioka, Masahiko ^a   Omori, Naoki ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETHANECHOL; CARBACHOL; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; HORMONE RECEPTOR BLOCKING AGENT; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; METHACHOLINE; UNCLASSIFIED DRUG;

ALLOSTERISM; ASSAY; BINDING AFFINITY; CHEMICAL STRUCTURE; CHIRALITY; DRUG RECEPTOR BINDING; HIGH THROUGHPUT SCREENING; HOMEOSTASIS; HUMAN; HYDROGEN BOND; NONHUMAN; RACEMIC MIXTURE; REVIEW; SEXUAL BEHAVIOR; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866730292     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.06.010     Document Type: Review

References (36)

1. J.P. Overington How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996
2. Y.C. Martin Do structurally similar molecules have similar biological activity? J. Med. Chem. 45 2002 4350 4358
3. T. Varin Latent hit series hidden in high-throughput screening data J. Med. Chem. 55 2012 1161 1170
4. H. Kubinyi Similarity and dissimilarity - a medicinal chemists view Prospect. Drug Discov. Des. 11 1998 225 252
5. F. Giordanetto Follow-on drugs: how far should chemists look? Drug Discov. Today 16 2011 722 732
6. P.J. Conn Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discov. 8 2009 41 54
7. M.R. Wood 'Molecular switches' on mGluR allosteric ligands that modulate modes of pharmacology Biochemistry 50 2011 2403 2410
8. J. Fischer, and C.R. Ganellin Analogue-based Drug Discovery 2006 Wiley-VCH
9. S. Perlman Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations Mol. Pharmacol. 51 1997 301 311
10. A.M.S. Murugaiah From the first selective non-peptide AT2 receptor agonist to structurally related antagonists J. Med. Chem. 55 2012 2265 2278
11. F. Lovering Escape from Flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 52 2009 6752 6756
12. J.E.S. Wikberg, and F. Mutulis Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction Nat. Rev. Drug Discov. 7 2008 307 323
13. W. Jiang Synthesis and characterization of pyrrolidine derivatives as potent agonists of the human melanocortin-4 receptor Bioorg. Med. Chem. Lett. 17 2007 6546 6552
14. C. Chen Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor Bioorg. Med. Chem. Lett. 18 2008 129 136
15. Soeberdt, M. et al. Myo Contract Ltd. Preparation of amides derived from substituted piperadinealkylamines as melanocortin-4 receptor antagonist. WO2004083208 A1
16. K.F. McClure Activation of the G-protein-coupled receptor 119: a conformation-based hypothesis for understanding agonist response J. Med. Chem. 54 2011 1948 1952
17. J.W. Black, and P. Leff Operational models of pharmacological agonism Proc. R. Soc. Lond. 220 1983 141 162
18. T. Kenakin, and A. Christopoulos Analytical pharmacology: the impact of numbers on pharmacology Trends Pharmacol. Sci. 32 2011 189 196
19. T.P. Kenakin A Pharmacology Primer: Theory, Applications, and Methods 3rd edn 2008 Academic Press pp. 81-100
20. S.A. Nickolls Understanding the effect of different assay formats on agonist parameters: a study using the μ-opioid receptor J. Biomol. Screen. 16 2011 706 716
21. S. Simon The effect of assay formats on the estimation of melanocortin agonist affinity and efficacy using the operation model of agonism Eur. J. Pharmacol. 615 2009 33 39
22. D.A. Sykes Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor Mol. Pharmacol. 76 2009 543 551
23. D. Hoyer, and H.W. Boddeke Partial agonists, full agonists, antagonists: dilemmas of definition Trends Pharmacol. Sci. 14 1993 270 275
24. P.J. Greasley, and J.C. Clapham Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing? Eur. J. Pharmacol. 553 2006 1 9
25. T.P. Kenakin Efficacy as a vector: the relative prevalence and paucity of inverse agonism Mol. Pharmacol. 65 2004 2 11
26. J. Giraldo How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue Drug Discov. Today 15 2010 411 415
27. Ellis, C. and the nature reviews drug discovery GPCR questionnaire participants. (2004). The state of GPCR research in 2004. Nat. Rev. Drug Discov. 3, 577-626
28. 2 receptor signaling Prog. Neuropsychopharmacol. 31 2007 348 356
29. P.G. Strange Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors Br. J. Pharmacol. 153 2008 1353 1363
30. T.P. Kenakin, and L.J. Miller Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 62 2010 265 304
31. H. Zhao Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective Drug Discov. Today 12 2007 149 155
32. R. Macarron Critical review of the role of HTS in drug discovery Drug Discov. Today 11 2006 277 279
33. S. Schann GPCR allosteric modulator discovery: silence is golden 3rd RSC/SCI Symposium on GPCRs in Medicinal Chemistry 2010
34. A. Bender Which aspects of HTS are empirically correlated with downstream success? Curr. Opin. Drug Discov. Dev. 11 2008 327 337
35. G. Semple Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119 J. Med. Chem. 51 2008 5172 5175
36. P. Iyer Molecular mechanism-based network-like similarity graphs reveal relationships between different types of receptor ligands and structural changes that determine agonistic, inverse-agonistic, and antagonistic effects J. Chem. Inf. Model. 51 2011 1281 1286